

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group



Final Appraisal Recommendation

Advice No: 4312 – December 2012

**Argatroban (Exembol®) 100 mg/ml concentrate
for solution for infusion**

Submission by Mitsubishi Tanabe Pharma Europe Ltd

Recommendation of the All Wales Medicines Strategy Group

Argatroban (Exembol®) is recommended as an option for use within NHS Wales for anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy.

The diagnosis should be confirmed by the HIPAA (heparin induced platelet activation assay) or an equivalent test. However, such confirmation must not delay the start of treatment.

Additional note:

- AWMSG is of the opinion that argatroban (Exembol®) is appropriate for specialist only prescribing within NHS Wales for the above recommendation.

In reaching the above recommendation AWMSG has taken account of the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in August 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation 4312: Argatroban (Exembol®) 100 mg/ml concentrate for solution for infusion. December 2012.